Advocate Group’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
AIM
FWIA
DLA
ETC
Advocate Group's BMY Position: Q2 2026 in Review
Advocate Group reduced its Bristol-Myers Squibb (BMY) stake by 4% in Q2 2026, selling an estimated $382K and leaving 160,303 shares worth $9.24M. The position accounts for 1.39% of the portfolio, ranked #29.
Advocate Group first reported a position in BMY in Q2 2022 and has held it in 17 quarters since. The position peaked at $10.1M in Q1 2026. 800 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Advocate Group held 160,303 shares of Bristol-Myers Squibb worth $9.24M as of Q2 2026.
- Advocate Group sold 6,653 Bristol-Myers Squibb shares in Q2 2026, an estimated $382K.
- Bristol-Myers Squibb made up 1.39% of Advocate Group's portfolio in Q2 2026, its #29 holding.
- Advocate Group first reported a position in Bristol-Myers Squibb in Q2 2022 and has held it in 17 quarters since.
- Advocate Group's Bristol-Myers Squibb position peaked at $10.1M in Q1 2026.
- 800 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Advocate Group's 13F filing for Q2 2026, filed 17 Jul 2026.